Vaccine . Development of a recombinant H9N2 influenza vaccine candidate against the Y280 lineage field virus and its protective efficacy

[tetano]

Vaccine


. 2021 Sep 14;S0264-410X(21)01149-X.
doi: 10.1016/j.vaccine.2021.08.089. Online ahead of print.
Development of a recombinant H9N2 influenza vaccine candidate against the Y280 lineage field virus and its protective efficacy


Do-Young Kim ¹ , Yong-Myung Kang ¹ , Hyun-Kyu Cho ¹ , Seo-Jeong Park ¹ , Myoung-Heon Lee ¹ , Youn-Jeong Lee ¹ , Hyun-Mi Kang ²



Affiliations

• PMID: 34535319
• DOI: 10.1016/j.vaccine.2021.08.089

Abstract

Since June 2020, a new H9N2 virus of the Y280 lineage has been epidemic in Korea. Initially, a Korean commercial vaccine against the Y280 and Y439 lineages of H9N2 was evaluated for use in SPF chickens. A single vaccination did not protect chickens against virus of the Y280 lineage, with no significant reduction in virus shedding and a 37.5% inhibition in virus recovery rate in cecal tonsil. rgHS314 was selected as a vaccine candidate, showing immunogenicity in SPF chickens, and was highly productive in eggs. Moreover, rgHS314 protected with high levels of protective immunity and significantly reduced virus shedding, with 100% and 83.3% inhibition of virus recovery in the cecal tonsil against homologous and heterologous challenge viruses, respectively. Taken together, these data suggest that a single vaccination with this recombinant vaccine candidate could elicit cross-reactive immune responses capable of protecting chickens against H9N2 viruses of the Y439 and Y280 lineages.

Keywords: Antigen cartography; H9N2; Reverse genetics; Vaccine; Y280 lineage.